MedTrace Logo

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

NCT04064879 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-09-28

No results posted yet for this study

Summary

The present study is being undertaken as a phase I study to determine the safety and feasibility of using adipose derived mesenchymal stem cell preparations (MSC) for treatment of CM. Intravenous and locally targeted stem cell treatment have already been reported in the context of treating various chronic pain conditions with early evidence of efficacy and a good safety profile. The treatment of CM is based on the model for treatment with botulinum where superficial facial and cranial injections are utilized. In addition, stem cells can be given intravenously as well.

Conditions

  • Chronic Migraine, Headache

Interventions

OTHER

AD-SVF

Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.

Sponsors & Collaborators

  • Cell Surgical Network Inc.

    collaborator INDUSTRY

  • Neurological Associates of West Los Angeles

    lead OTHER

Principal Investigators

  • Sheldon E Jordan, MD, FAAN · Neurological Associates of West Los Angeles

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-16
Primary Completion
2023-08-15
Completion
2023-08-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064879 on ClinicalTrials.gov